Schaeffer Anthony J
Department of Urology, Feinberg School of Medicine, Northwestern University, Tarry 11-715, Chicago, IL 60611, USA.
Int J Antimicrob Agents. 2004 Sep;24 Suppl 1:S49-52. doi: 10.1016/j.ijantimicag.2004.02.009.
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a disabling condition that is poorly understood. The National Institutes of Diabetes and Digestive and Kidney Diseases-sponsored Collaborative Research Network has developed a symptom index, formed a cohort study, a case control study, a full-scale randomised clinical trial, a resource utilisation study and clinical trials, as well as basic research studies, in an effort to better understand and manage patients with this condition. Cohort, case control and resource utilisation studies have confirmed the substantial impact of CP/CPPS. Clinical trials in basic research suggest that anti-inflammatory therapy and alpha-blocker therapy may be effective. The minority of patients with acute or chronic bacterial prostatitis continues to respond favourably to oral fluoroquinolone therapy.
慢性前列腺炎/慢性盆腔疼痛综合征（CP/CPPS）是一种难以理解的致残性疾病。美国国立糖尿病、消化和肾脏疾病研究所资助的协作研究网络已经制定了症状指数，开展了队列研究、病例对照研究、全面随机临床试验、资源利用研究和临床试验，以及基础研究，以更好地了解和管理患有这种疾病的患者。队列研究、病例对照研究和资源利用研究已经证实了CP/CPPS的重大影响。基础研究中的临床试验表明，抗炎治疗和α受体阻滞剂治疗可能有效。少数急性或慢性细菌性前列腺炎患者继续对口服氟喹诺酮治疗反应良好。
